1. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1211,
1999,
Page 2-2
&NA;,
Preview
|
PDF (850KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
2. |
Don't prescribe zanamivir for flu this winter, says UK NICE |
|
Inpharma Weekly,
Volume &NA;,
Issue 1211,
1999,
Page 3-3
&NA;,
Preview
|
PDF (807KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
3. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1211,
1999,
Page 4-4
&NA;,
Preview
|
PDF (766KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
4. |
Tamoxifen prophylaxis and QOL |
|
Inpharma Weekly,
Volume &NA;,
Issue 1211,
1999,
Page 5-5
&NA;,
Preview
|
PDF (751KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
5. |
Olanzapine news from the 11th World Congress of PsychiatryHamburg, Germany August 1999 |
|
Inpharma Weekly,
Volume &NA;,
Issue 1211,
1999,
Page 6-7
&NA;,
Preview
|
PDF (1567KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
6. |
Trastuzumabno adverse impact on QOL in breast cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1211,
1999,
Page 7-7
&NA;,
Preview
|
PDF (767KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
7. |
aaATIII promising in cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1211,
1999,
Page 8-8
&NA;,
Preview
|
PDF (799KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
8. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1211,
1999,
Page 9-9
&NA;,
Preview
|
PDF (764KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
9. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1211,
1999,
Page 10-10
&NA;,
Preview
|
PDF (786KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
10. |
Botulinum toxin type Aputting a poison to good use |
|
Inpharma Weekly,
Volume &NA;,
Issue 1211,
1999,
Page 11-12
Jo Dalton,
Preview
|
PDF (1735KB)
|
|
摘要:
‘Poison can be employed as a means for destruction of life or as a treatment for the sick’. Such is the case with botulinum toxin type A, said Dr Roger Aoki from Allergan Inc., US, speaking at the 4th Congress of the European Federation of Neurological Societies [Lisbon, Portugal; September 1999]. Allergan's botulinum toxin type A purified neurotoxin complex [‘BOTOX’] provides a particularly effective approach to the localised treatment of disorders associated with muscle overactivity, with neglible adverse effects. Some of the most recent data on the use of botulinum toxin type A in such indications were discussed at the congress.
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|